|1.||Ratti, Emiliangelo: 2 articles (12/2013 - 12/2013)|
|2.||Merlo-Pich, Emilio: 2 articles (12/2013 - 07/2011)|
|3.||Trist, David G: 2 articles (12/2013 - 12/2013)|
|4.||Thompson, J P: 1 article (03/2015)|
|5.||Novikova, E: 1 article (03/2015)|
|6.||Eberhart, L H: 1 article (03/2015)|
|7.||Brigandi, R A: 1 article (03/2015)|
|8.||Noble, R: 1 article (03/2015)|
|9.||Russ, S F: 1 article (03/2015)|
|10.||Kranke, P: 1 article (03/2015)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
12/01/2013 - "Vestipitant improved sleep maintenance in patients with primary insomnia, with no associated next-day cognitive impairment. "
12/01/2013 - "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia."
12/01/2013 - "However, in acute studies in insomnia, both vestipitant and casopitant at 15 mg and 30 mg, respectively, significantly reduced latency to persistent sleep, wakenings after sleep onset and increased total sleep time by similar amounts. "
12/01/2013 - "Investigate the hypnotic effects of repeated doses of neurokinin-1 receptor antagonist, vestipitant, in primary insomnia. "
|2.||Postoperative Nausea and Vomiting (PONV)
03/01/2015 - "Vestipitant is a neurokinin 1 (NK-1) receptor antagonist that is effective for prophylaxis, but its efficacy for treating established PONV is unknown. "
03/01/2015 - "These data suggest that vestipitant may be a useful agent for the management of PONV, similar to other NK-1 antagonists. "
03/01/2015 - "This study was performed to evaluate the efficacy and safety of vestipitant, compared with ondansetron for the treatment of breakthrough PONV in patients who had already received prophylactic ondansetron before surgery. "
03/01/2015 - "However, vestipitant was superior to ondansetron in decreasing episodes of postoperative emesis and retching. "
03/01/2015 - "All doses of vestipitant were non-inferior to ondansetron in treating PONV after failed prophylaxis with ondansetron. "
07/01/2011 - "No specific relationships were observed between tinnitus intensity and vestipitant plasma concentrations. "
07/01/2011 - "However, a statistically significant worsening of tinnitus intensity and distress scores was observed after vestipitant compared with placebo for the mean data collected over the treatment period. "
07/01/2011 - "A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus."
07/01/2011 - "Although well-tolerated vestipitant, alone or in combination with paroxetine, was not effective in ameliorating tinnitus in this patient group."
07/01/2011 - "Vestipitant was investigated for potential effect against chronic tinnitus as a stand-alone treatment and in conjunction with a selective serotonin reuptake inhibitor, paroxetine. "
11/02/2010 - "Vestipitant (1) is a novel NK1 antagonist currently under investigation for the treatment of CNS disorders and emesis. "
03/01/2015 - "Although overall efficacy was non-inferior between vestipitant and ondansetron, the rate of emesis was lower with vestipitant. "
03/01/2015 - "Of 527 surgical patients, 130 (25%) had breakthrough PONV and were equally randomized to one of six i.v. doses of vestipitant (4-36 mg) or ondansetron 4 mg. The primary endpoint was the rate of patients exhibiting complete response, defined as no emesis and no further rescue medication from 10 min after infusion up to 24 h after surgery or hospital discharge. "
|1.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|5.||Serotonin (5 Hydroxytryptamine)